down arrow

Rapt Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US75382E1091
USD
34.47
2.14 (6.62%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

31.7234.73

52 Week

5.6642.39
Valuation
Technical
Day's Volume

CASH

441.07 k

Shareholding (Mar 2025)

FII

18.80%

Held by 66 FIIs

DII

19.51%

Held by 29 DIIs

Promoter

48.46%

How big is Rapt Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Rapt Therapeutics, Inc. has a market capitalization of 129.64 million, with net sales of 0.00 million and a net profit of -116.50 million over the latest four quarters. As of December 2024, the company reported shareholder's funds of 189.90 million and total assets of 240.32 million.

Market Cap: As of Jun 18, Rapt Therapeutics, Inc. has a market capitalization of 129.64 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Rapt Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -116.50 million.<BR><BR>Balance Sheet Snapshot: As of December 2024, the company reported shareholder's funds of 189.90 million and total assets of 240.32 million.

Read More

What does Rapt Therapeutics, Inc. do?

22-Jun-2025

Rapt Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for oncology and inflammatory diseases. It has a market cap of $129.64 million and reported a net profit loss of $17 million as of March 2025.

Overview: <BR>Rapt Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -17 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 129.64 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.00 <BR>Return on Equity: -65.69% <BR>Price to Book: 0.73 <BR><BR>Contact Details: <BR>Address: 561 Eccles Ave, SOUTH SAN FRANCISCO CA: 94080-1906 <BR>Tel: 1 650 4899000 <BR>Website: https://www.rapt.com/

Read More

Who are in the management team of Rapt Therapeutics, Inc.?

22-Jun-2025

As of March 2022, Rapt Therapeutics, Inc.'s management team includes Dr. Brian Wong as President and CEO, with independent directors Mr. Peter Svennilson, Dr. Michael Giordano, Dr. Mary Gray, Linda Kozick, and Mr. William Rieflin on the Board.

As of March 2022, the management team of Rapt Therapeutics, Inc. includes Dr. Brian Wong, who serves as the President, Chief Executive Officer, and Director. Additionally, the Board of Directors features Mr. Peter Svennilson, Dr. Michael Giordano, Dr. Mary Gray, Linda Kozick, and Mr. William Rieflin, all of whom hold independent director positions.

Read More

Is Rapt Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of May 11, 2023, Rapt Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify" due to negative financial metrics, including a P/E ratio not applicable from losses, a Price to Book Value of 0.87, an EV to EBITDA of 0.19, and a troubling ROE of -65.69%, despite a recent stock surge of 622.33%.

As of 11 May 2023, the valuation grade for Rapt Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued, given its negative performance metrics, including a P/E ratio that is not applicable due to losses, a Price to Book Value of 0.87, and an EV to EBITDA ratio of 0.19. Additionally, the Return on Equity (ROE) stands at a concerning -65.69%, highlighting ongoing financial struggles.<BR><BR>In comparison to its peers, Rapt Therapeutics, Inc. shows a stark contrast to Tarsus Pharmaceuticals, Inc., which has a P/E ratio of -16.08 and an EV to EBITDA of -12.26, and Viridian Therapeutics, Inc. with a P/E of -4.13 and an EV to EBITDA of -1.77. This suggests that Rapt's valuation does not align favorably within its industry context. Despite a remarkable recent stock performance, with a one-week return of 622.33% compared to a slight decline in the S&P 500, the underlying financial ratios indicate that the stock is not justified at its current price of 7.44.

Read More

Is Rapt Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, Rapt Therapeutics, Inc. shows a bullish trend with strong indicators, outperforming the S&P 500 significantly, although caution is advised due to a mildly bearish signal from the Bollinger Bands on the monthly timeframe.

As of 4 September 2025, the technical trend for Rapt Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD is bullish, and the daily moving averages also confirm a bullish trend. The KST is bullish on a weekly basis, and the On-Balance Volume (OBV) is bullish for both weekly and monthly periods. However, the Bollinger Bands show a mildly bearish signal on the monthly timeframe, indicating some caution.<BR><BR>In terms of performance, Rapt Therapeutics has significantly outperformed the S&P 500 over the past week (30.57% vs. 1.05%) and month (74.77% vs. 2.33%), while the year-to-date return of 62.18% also surpasses the S&P's 12.22%. Overall, the technical indicators suggest a strong bullish sentiment, despite some mixed signals in the longer-term trends.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 220 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.01

stock-summary
Return on Equity

-64.77%

stock-summary
Price to Book

1.34

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-18 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
205.04%
0%
205.04%
6 Months
336.11%
0%
336.11%
1 Year
259.06%
0%
259.06%
2 Years
-73.35%
0%
-73.35%
3 Years
95.85%
0%
95.85%
4 Years
-85.67%
0%
-85.67%
5 Years
-80.2%
0%
-80.2%

Rapt Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Rapt Therapeutics, Inc. technically bullish or bearish?

As of 4 September 2025, the technical trend for Rapt Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD is bullish, and the daily moving averages also confirm a bullish trend. The KST is bullish on a weekly basis, and the On-Balance Volume (OBV) is bullish for both weekly and monthly periods. However, the Bollinger Bands show a mildly bearish signal on the monthly timeframe, indicating some caution. In terms of performance, Rapt Therapeutics has significantly outperformed the S&P 500 over the past week (30.57% vs. 1.05%) and month (74.77% vs. 2.33%), while the year-to-date return of 62.18% also surpasses the S&P's 12.22%. Overall, the technical indicators suggest a strong bullish sentiment, despite some mixed signals in the longer-term trends....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-179.74%
EBIT to Interest (avg)
-95.52
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.87
EV to EBIT
0.18
EV to EBITDA
0.19
EV to Capital Employed
-22.18
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-65.69%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 42 Schemes (13.21%)

Foreign Institutions

Held by 66 Foreign Institutions (18.8%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -2.33% vs 67.67% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.30",
          "val2": "-19.00",
          "chgp": "-1.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.60",
          "val2": "-17.20",
          "chgp": "-2.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -11.22% vs -39.38% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-132.60",
          "val2": "-123.50",
          "chgp": "-7.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-129.90",
          "val2": "-116.80",
          "chgp": "-11.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-19.30
-19.00
-1.58%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-17.60
-17.20
-2.33%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -2.33% vs 67.67% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-132.60
-123.50
-7.37%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-129.90
-116.80
-11.22%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -11.22% vs -39.38% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Rapt Therapeutics, Inc. stock-summary
stock-summary
Rapt Therapeutics, Inc.
Pharmaceuticals & Biotechnology
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. It has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues.
Company Coordinates stock-summary
Company Details
561 Eccles Ave , SOUTH SAN FRANCISCO CA : 94080-1906
stock-summary
Tel: 1 650 4899000
stock-summary
https://www.rapt.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."